[Mucoviscidosis].
D000293:Adolescent; D000336:Aerosols; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications; D001827:Body Height; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D004035:Diet Therapy; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008171:Lung Diseases / Q000150:complications; D008297:Male; D026741:Physical Therapy Modalities; D011379:Prognosis; D044469:Racial Groups; D014481:United States
D000336:Aerosols; D000900:Anti-Bacterial Agents
Mucoviscidose.